Point72 Asset Management L.P. Has $6.25 Million Position in ABIVAX Société Anonyme (NASDAQ:ABVX)

Point72 Asset Management L.P. lifted its stake in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 28.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 542,900 shares of the company's stock after buying an additional 119,300 shares during the period. Point72 Asset Management L.P. owned approximately 0.86% of ABIVAX Société Anonyme worth $6,254,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in ABVX. BNP Paribas Financial Markets lifted its position in shares of ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after acquiring an additional 5,900 shares during the period. Walleye Capital LLC increased its position in shares of ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock worth $2,965,000 after purchasing an additional 80,807 shares during the period. Finally, abrdn plc raised its stake in ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company's stock valued at $3,645,000 after purchasing an additional 198,225 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a "strong-buy" rating in a research note on Wednesday, December 4th. JMP Securities initiated coverage on shares of ABIVAX Société Anonyme in a report on Wednesday, December 4th. They set an "outperform" rating and a $33.00 price target for the company. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, ABIVAX Société Anonyme presently has an average rating of "Buy" and a consensus price target of $38.67.

ABIVAX Société Anonyme Stock Down 4.0 %

NASDAQ ABVX traded down $0.35 during trading on Monday, hitting $8.46. 22,553 shares of the company's stock were exchanged, compared to its average volume of 93,306. The stock's 50 day moving average price is $9.73 and its two-hundred day moving average price is $11.51. ABIVAX Société Anonyme has a fifty-two week low of $8.06 and a fifty-two week high of $17.02.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.